The initial reason for writing Complementary and Alternative Medicine: An Evidence-
Based Approach was the need to examine research evidence and claims purported by
advocates, clinicians, and researchers of complementary and alternative medicine
(CAM) regarding its effectiveness. Both of us had previous experience with certain of
these therapies since we had worked with American Indians who used alternative spiritual-
indigenous medical approaches to health-related problems. Joseph Jacobs, a
Mohawk, grew up using many of these healing practices.
The latest diagnostic and therapeutic modalities in the management of coronary artery dis‐
ease by coronary artery bypass graft surgery and by percutaneous coronary intervention
with stenting and in the interventional management of other atherosclerotic vascular disease
have led to a reduction in cardiovascular mortality and morbidity. This book entitled Artery
Bypass provides an excellent update on these advances which every physician seeing pa‐
tients with atherosclerotic vascular disease should be familiar with.
(BQ) Part 2 book "Braunwald's heart disease - Review and assessment" presents the following contents: Preventive cardiology; atherosclerotic cardiovascular disease; diseases of the heart, pericardium, and pulmonary vascular bed; cardiovascular disease in special populations; cardiovascular disease and disorders of other organs.
In 1856, Rudolf Virchow published “Cellular pathology” based on macroscopic and
microscopic observation of diseases, and described a triad of factors on thrombosis. The
three components were vascular change, blood flow alteration, and abnormalities of blood
constituents. Although Virchow originally referred to venous thrombosis, the theory can
also be applied to arterial thrombosis, and it is considered that atherothrombus formation is
regulated by the thrombogenicity of exposed plaque contents, local hemorheology, and
Angiotensin-converting–enzyme (ACE) inhibitors are effective in reducing the risk of
heart failure, myocardial infarction, and death from cardiovascular causes in patients
with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been
shown to reduce atherosclerotic complications in patients who have vascular disease
without heart failure.